Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × Letrozole × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 52 Neoplasms 6 Endometrial Neoplasms 5 Ovarian Neoplasms 4 Carcinoma, Intraductal, Noninfiltrating 3 Advanced Breast Cancer 3 Prostatic Neoplasms 2 Polycystic Ovary Syndrome 2 Neoplasms by Site 2 Neoplasm Metastasis 2 Hereditary Sensory and Autonomic Neuropathies 2 Breast Neoplasms, Male 2 Breast Diseases 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Low-Grade Serous Ovarian Cancer 1 Low Grade Serous Ovarian Cancer 1 Locoregional Recurrence 1 Leiomyoma 1 Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 HR+/HER2- Breast Cancer 1 Fallopian Tube Neoplasms 1 Cystadenocarcinoma, Serous 1

Interventions

Letrozole 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡